Public Health, Health Services Research and HTA




EUCAPA - European Capacity Building for Patients is a new EU4HEALTH initiative for the training of patients and their representatives in Health Technology Assessment (HTA) - the multidisciplinary and systematic process that evaluates the added value of a health technology in comparison with other existing or new ones.

Through EUCAPA, patients and their representatives will gain the necessary skills, knowledge, and understanding of HTA to constructively participate in HTA decision-making processes, present their lived experience in assessing health technologies, and advocate for equitable access to innovative treatments.

The project is conducted by a consortium composed of EURORDIS, the European Patients Forum (EPF) and UMIT TIROL to build the capacities and knowledge for patient advocates to participate in HTAs at the national or European level.

EUCAPA will ensure that patients and patient organisations have the necessary knowledge of the HTA process to be meaningfully involved in HTA (both in scientific consultations and assessments), as foreseen by the new Regulation on HTA (EU) 2021/2282, which will start assessing health technologies in January 2025.

Focusing mostly – but not exclusively – on people living with cancer and people who need advanced therapy medicinal products (ATMPs), EUCAPA is set to last two years and will offer three types of trainings:

  • Online introductory training aimed for the larger patient community and patient organisations who need to know more about HTA to participate in joint clinical assessments (JCAs) and scientific consultations (JSCs)

  • Online fast-track training enabling patient to gain the essential skills needed to participate as patient experts, which are aimed at those who will participate in JCAs and JSCs at short notice

  • In-person extended training that will further develop concepts, skills, and knowledge from the two previous trainings

UMIT TIROL is involved in several Work Packages (WP). In WP 2, the task led by UMIT TIROL is to conduct a review of existing involvement of patients in HTA. The development of the curricula for the fast track and the extended training is mainly part of UMIT TIROL with the input of the two other consortia partners. So, the training is based on the consortium's joint experience in patient advocacy, international HTA research and more than two decades of education in HTA (

WP 3 task led by UMIT TIROL is to develop the training materials, and to plan, organize, prepare, and execute the fast track and the executive training. The extended training as an in-person training will be conducted at UMIT TIROL in Hall in Tirol, Austria.

The EUCAPA training comes at a crucial time with the current implementation of the new Regulation on HTAs (EU) 2021/2282. The HTA Regulation’s framework has significantly increased the role of patient experts, so the need to further and better train patients in HTA has become vital. Responding to this need, EUCAPA will become the largest coordinated HTA training for patient advocates provided to date.

EUCAPA is a EU4Health project and will receive funding under the Grant Agreement number: 101101222.

For more information go to:



EURORDIS-Rare Diseases Europe is a unique, non-profit alliance of over 1,000 rare disease patient organisations from 74 countries that work together to improve the lives of the 30 million people living with a rare disease in Europe. By connecting patients, families, and patient groups, as well as by bringing together all stakeholders and mobilising the rare disease community, EURORDIS strengthens the patient voice and shapes research, policies and patient services.

About EPF

The European Patients’ Forum (EPF) is an independent non-profit, non-governmental umbrella organisation of patient organisations across Europe and across disease-areas. EPF’s 78 members include disease-specific patient groups active at EU level and national coalitions of patients.


Contact at UMIT TIROL:
Dr. med. Silke Siebert
Work Package Coordinator EUCAPA
Email:, Phone.: +43 50 8648 4019


Contact at EURODIS (Project Lead):
Julien Poulain
Communications Manager
EURORDIS-Rare Diseases Europe
Email:, Phone: +33 6 42 98 14 32


Total Project Budget:

UMIT TIROL 306.215,84 EUR
EU contribution: 183.729,48 EUR

Duration: 01/03/2023 – 01/03/2025